These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31561065)

  • 1. Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling.
    Hastie R; Brownfoot FC; Cannon P; Nguyen V; Tuohey L; Hannan NJ; Tong S; Kaitu'u-Lino TJ
    Placenta; 2019 Nov; 87():53-57. PubMed ID: 31561065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion.
    Hastie R; Brownfoot FC; Pritchard N; Hannan NJ; Cannon P; Nguyen V; Palmer K; Beard S; Tong S; Kaitu'u-Lino TJ
    Hypertension; 2019 Mar; 73(3):659-670. PubMed ID: 30636550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ
    Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction.
    Brownfoot FC; Hannan NJ; Cannon P; Nguyen V; Hastie R; Parry LJ; Senadheera S; Tuohey L; Tong S; Kaitu'u-Lino TJ
    EBioMedicine; 2019 Mar; 41():636-648. PubMed ID: 30824385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling.
    Whigham CA; Hastie R; Hannan NJ; Brownfoot F; Pritchard N; Cannon P; Nguyen TV; Kandel M; Masci J; Tong S; Kaitu'u-Lino TJ
    Placenta; 2021 Oct; 114():22-28. PubMed ID: 34418751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
    Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia.
    Brownfoot FC; Tong S; Hannan NJ; Binder NK; Walker SP; Cannon P; Hastie R; Onda K; Kaitu'u-Lino TJ
    Hypertension; 2015 Sep; 66(3):687-97; discussion 445. PubMed ID: 26222708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta.
    Ye L; Gratton A; Hannan NJ; Cannon P; Deo M; Palmer KR; Tong S; Kaitu'u-Lino TJ; Brownfoot FC
    Placenta; 2016 Dec; 48():110-118. PubMed ID: 27871461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion.
    Tong S; Kaitu'u-Lino TJ; Onda K; Beard S; Hastie R; Binder NK; Cluver C; Tuohey L; Whitehead C; Brownfoot F; De Silva M; Hannan NJ
    Hypertension; 2015 Nov; 66(5):1073-81. PubMed ID: 26324507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta.
    Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Kaitu'u-Lino TJ
    BMC Pregnancy Childbirth; 2016 May; 16():117. PubMed ID: 27207105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimethylamine N-Oxide increases soluble fms-like tyrosine Kinase-1 in human placenta via NADPH oxidase dependent ROS accumulation.
    Chang QX; Chen X; Ming-Xin Yang ; Zang NL; Li LQ; Zhong N; Xia LX; Huang QT; Zhong M
    Placenta; 2021 Jan; 103():134-140. PubMed ID: 33120049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome.
    Hastie R; Ye L; Hannan NJ; Brownfoot FC; Cannon P; Nguyen V; Tong S; Kaitu'u-Lino TJ
    Pregnancy Hypertens; 2018 Oct; 14():125-130. PubMed ID: 30527099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia.
    Hannan NJ; Binder NK; Beard S; Nguyen TV; Kaitu'u-Lino TJ; Tong S
    PLoS One; 2018; 13(4):e0187082. PubMed ID: 29641523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia.
    Binder NK; Brownfoot FC; Beard S; Cannon P; Nguyen TV; Tong S; Kaitu'u-Lino TJ; Hannan NJ
    Pregnancy Hypertens; 2020 Oct; 22():86-92. PubMed ID: 32758704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta.
    Kaitu'u-Lino TJ; Brownfoot FC; Hastie R; Chand A; Cannon P; Deo M; Tuohey L; Whitehead C; Hannan NJ; Tong S
    Hypertension; 2017 Nov; 70(5):1014-1024. PubMed ID: 28947613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production.
    Palmer KR; Tong S; Tuohey L; Cannon P; Ye L; Hannan NJ; Brownfoot FC; Illanes SE; Kaitu'u-Lino TJ
    Biol Reprod; 2016 Mar; 94(3):59. PubMed ID: 26819475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioflavonoid luteolin prevents sFlt-1 release via HIF-1α inhibition in cultured human placenta.
    Eddy AC; Chiang CY; Rajakumar A; Spradley FT; Dauer P; Granger JP; Rana S
    FASEB J; 2023 Aug; 37(8):e23078. PubMed ID: 37405762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia.
    Zhao Y; Zheng Y; Liu X; Luo Q; Wu D; Liu X; Zou L
    Mol Hum Reprod; 2018 Mar; 24(3):158-169. PubMed ID: 29325127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone Induced Blocking Factor Reduces Hypertension and Placental Mitochondrial Dysfunction in Response to sFlt-1 during Pregnancy.
    Deer E; Jones J; Cornelius DC; Comley K; Herrock O; Campbell N; Fitzgerald S; Ibrahim T; LaMarca B; Amaral LM
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.